DXVX Begins Full-Scale Development of Broad-Spectrum Antiviral Therapeutic for "Disease X" Response View original image

DXVX is set to embark in earnest on developing a broad-spectrum antiviral treatment to prepare for future pandemics. This follows the completion of the final agreement for a national research and development project led by the Ministry of Health and Welfare and the Korea Health Industry Development Institute.


On May 22, the company announced that it has signed the final agreement for the “Development of Antiviral Therapeutics Against RNA Virus Infectious Diseases (Disease X)” project, which is part of the “2026 First Health and Medical Technology R&D Program” overseen by the Ministry of Health and Welfare.


Within this project, DXVX will serve as the lead research and development institution, conducting research on “Development of a mutation-independent, broad-spectrum antiviral peptide therapeutic for Disease X response and IND approval.” The company plans to receive government funding totaling 2.9 billion won over up to four years (2+2 years) and will proceed with stepwise development from candidate discovery to non-clinical research and Investigational New Drug (IND) approval.


The core technology is the “LEAD™ (Lipid Envelope Antiviral Disruption)” platform, a broad-spectrum antiviral peptide jointly developed by LukaAIcell and Professor Nam-Joon Cho’s research team at Nanyang Technological University (NTU), Singapore. While conventional antiviral treatments have targeted specific protein mutations, this technology is based on a mechanism that directly destroys the lipid membrane composing the viral envelope by recognizing its curvature.


This approach is characterized by being less affected by specific mutations. It is said that this technology can be applied to a wide range of RNA viruses with lipid envelopes and a size of 200nm or less, including COVID-19, SARS, MERS, influenza, Zika, dengue, Nipah virus, and rabies virus, as well as severe fever with thrombocytopenia syndrome (SFTS), hantavirus, and Ebola virus. In particular, attention is being paid to its potential for addressing hantavirus, which has raised concerns following recent cruise ship outbreaks, and Ebola virus, which is spreading in Africa.


DXVX plans to further strengthen joint research with LukaAIcell, the original technology provider, and Professor Nam-Joon Cho’s team to accelerate development. The company is also considering expanding new indications, such as hantavirus and severe fever with thrombocytopenia syndrome (SFTS), which have recently drawn attention due to the lack of available treatments.


The company aims to secure treatment options that can be deployed immediately during the initial public health response gap period before vaccine development and supply are completed. The company emphasized the significance of being able to respond to new virus variants or unknown infectious diseases such as “Disease X” using the same platform technology.


Lee Gyuhang, Executive Director (PharmD) at DXVX and chief investigator for this project, said, “The signing of this agreement is meaningful in that the full-scale development is now underway, based on our antiviral R&D capabilities and experience in executing national projects. Through the development of therapeutics that can proactively address future infectious disease crises, we will contribute to strengthening national health security.”



This agreement is being regarded as significant because it marks the official launch of DXVX’s efforts to develop pandemic-response therapeutics based on a broad-spectrum antiviral platform technology that is less affected by viral mutations.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing